270 related articles for article (PubMed ID: 27586798)
21. An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling.
El Malki K; Karbach SH; Huppert J; Zayoud M; Reissig S; Schüler R; Nikolaev A; Karram K; Münzel T; Kuhlmann CR; Luhmann HJ; von Stebut E; Wörtge S; Kurschus FC; Waisman A
J Invest Dermatol; 2013 Feb; 133(2):441-51. PubMed ID: 22951726
[TBL] [Abstract][Full Text] [Related]
22. Antrodia cinnamomea Extract Inhibits Th17 Cell Differentiation and Ameliorates Imiquimod-Induced Psoriasiform Skin Inflammation.
Li MH; Wu HC; Yao HJ; Lin CC; Wen SF; Pan IH
Am J Chin Med; 2015; 43(7):1401-17. PubMed ID: 26477794
[TBL] [Abstract][Full Text] [Related]
23. Antagonization of IL-17A Attenuates Skin Inflammation and Vascular Dysfunction in Mouse Models of Psoriasis.
Schüler R; Brand A; Klebow S; Wild J; Veras FP; Ullmann E; Roohani S; Kolbinger F; Kossmann S; Wohn C; Daiber A; Münzel T; Wenzel P; Waisman A; Clausen BE; Karbach S
J Invest Dermatol; 2019 Mar; 139(3):638-647. PubMed ID: 30367871
[TBL] [Abstract][Full Text] [Related]
24. GILZ regulates Th17 responses and restrains IL-17-mediated skin inflammation.
Jones SA; Perera DN; Fan H; Russ BE; Harris J; Morand EF
J Autoimmun; 2015 Jul; 61():73-80. PubMed ID: 26077873
[TBL] [Abstract][Full Text] [Related]
25. Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun).
Wagner EF
Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i86-88. PubMed ID: 19995753
[TBL] [Abstract][Full Text] [Related]
26. Implantable synthetic cytokine converter cells with AND-gate logic treat experimental psoriasis.
Schukur L; Geering B; Charpin-El Hamri G; Fussenegger M
Sci Transl Med; 2015 Dec; 7(318):318ra201. PubMed ID: 26676608
[TBL] [Abstract][Full Text] [Related]
27. Chronic systemic inflammation originating from epithelial tissues.
Uluçkan Ö; Wagner EF
FEBS J; 2017 Feb; 284(4):505-516. PubMed ID: 27650997
[TBL] [Abstract][Full Text] [Related]
28. IκBζ: A key protein in the pathogenesis of psoriasis.
Johansen C
Cytokine; 2016 Feb; 78():20-1. PubMed ID: 26615569
[TBL] [Abstract][Full Text] [Related]
29. Psoriatic inflammation causes hepatic inflammation with concomitant dysregulation in hepatic metabolism via IL-17A/IL-17 receptor signaling in a murine model.
Al-Harbi NO; Nadeem A; Al-Harbi MM; Zoheir KMA; Ansari MA; El-Sherbeeny AM; Alanazi KM; Alotaibi MR; Ahmad SF
Immunobiology; 2017 Feb; 222(2):128-136. PubMed ID: 27773660
[TBL] [Abstract][Full Text] [Related]
30. Protection from Psoriasis-Related Thrombosis after Inhibition of IL-23 or IL-17A.
Li Y; Golden JB; Camhi MI; Zhang X; Fritz Y; Diaconu D; Ivanco TL; Simon DI; Kikly K; McCormick TS; Wang Y; Ward NL
J Invest Dermatol; 2018 Feb; 138(2):310-315. PubMed ID: 28951241
[TBL] [Abstract][Full Text] [Related]
31. IL-1RL2 and its ligands contribute to the cytokine network in psoriasis.
Blumberg H; Dinh H; Dean C; Trueblood ES; Bailey K; Shows D; Bhagavathula N; Aslam MN; Varani J; Towne JE; Sims JE
J Immunol; 2010 Oct; 185(7):4354-62. PubMed ID: 20833839
[TBL] [Abstract][Full Text] [Related]
32. IL-23-mediated epidermal hyperplasia is dependent on IL-6.
Lindroos J; Svensson L; Norsgaard H; Lovato P; Moller K; Hagedorn PH; Olsen GM; Labuda T
J Invest Dermatol; 2011 May; 131(5):1110-8. PubMed ID: 21289639
[TBL] [Abstract][Full Text] [Related]
33. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A.
Rizzo HL; Kagami S; Phillips KG; Kurtz SE; Jacques SL; Blauvelt A
J Immunol; 2011 Feb; 186(3):1495-502. PubMed ID: 21172868
[TBL] [Abstract][Full Text] [Related]
34. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model.
Nakajima K; Kanda T; Takaishi M; Shiga T; Miyoshi K; Nakajima H; Kamijima R; Tarutani M; Benson JM; Elloso MM; Gutshall LL; Naso MF; Iwakura Y; DiGiovanni J; Sano S
J Immunol; 2011 Apr; 186(7):4481-9. PubMed ID: 21346238
[TBL] [Abstract][Full Text] [Related]
35. Expression of IL-33 in the epidermis: The mechanism of induction by IL-17.
Meephansan J; Komine M; Tsuda H; Karakawa M; Tominaga S; Ohtsuki M
J Dermatol Sci; 2013 Aug; 71(2):107-14. PubMed ID: 23764374
[TBL] [Abstract][Full Text] [Related]
36. CIKS/Act1-mediated signaling by IL-17 cytokines in context: implications for how a CIKS gene variant may predispose to psoriasis.
Sønder SU; Paun A; Ha HL; Johnson PF; Siebenlist U
J Immunol; 2012 Jun; 188(12):5906-14. PubMed ID: 22581863
[TBL] [Abstract][Full Text] [Related]
37. IL-37 ameliorates the inflammatory process in psoriasis by suppressing proinflammatory cytokine production.
Teng X; Hu Z; Wei X; Wang Z; Guan T; Liu N; Liu X; Ye N; Deng G; Luo C; Huang N; Sun C; Xu M; Zhou X; Deng H; Edwards CK; Chen X; Wang X; Cui K; Wei Y; Li J
J Immunol; 2014 Feb; 192(4):1815-23. PubMed ID: 24453242
[TBL] [Abstract][Full Text] [Related]
38. Interleukin 17A: toward a new understanding of psoriasis pathogenesis.
Lynde CW; Poulin Y; Vender R; Bourcier M; Khalil S
J Am Acad Dermatol; 2014 Jul; 71(1):141-50. PubMed ID: 24655820
[TBL] [Abstract][Full Text] [Related]
39. Effects of inflammatory and anti-inflammatory cytokines on the bone.
Schett G
Eur J Clin Invest; 2011 Dec; 41(12):1361-6. PubMed ID: 21615394
[TBL] [Abstract][Full Text] [Related]
40. Egr-1 is a key regulator of IL-17A-induced psoriasin upregulation in psoriasis.
Jeong SH; Kim HJ; Jang Y; Ryu WI; Lee H; Kim JH; Bae HC; Choi JE; Kye YC; Son SW
Exp Dermatol; 2014 Dec; 23(12):890-5. PubMed ID: 25256120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
